4,7,7-Trimethyl-2,3-dioxo-bicyclo[2.2.1]heptane-1-carboxylic acid, 95.0%, 250mg

Methyl 5-hydroxy-2-nitrobenzoate, 97%, 5g

trans-Bis(acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II)>95.0%(T)1g

Colonne capillaire GC ROTI®Cap-1, 25 m, 0,32 mm, 0,50 µm, 1 pièce(s)

1-(2,6-Dichloropyridin-4-yl)ethanone, 95.0%, 5g

ethyl anilino(oxo)acetate, 97%, 1g

5-Chloro-2-phenyl-1H-indole, 95.0%, 1g

ethyl 5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylate, 98.0%, 100mg

(2R,3S,4R,5R)-2-(Hydroxymethyl)-5-(6-(methylamino)-9H-purin-9-yl)tetrahydrofuran-3,4-diol, 95.0%, 1g

5-Bromo N-methylnicotinamide, 97.0%, 25g

[3-(3-phenylpropoxy)phenyl]amine hydrochloride, 95.0%, 1g

Morpholine-3-carboxylic acid hydrochloride, 97.0%, 1g

N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-S-[(4-methoxyphenyl)diphenylmethyl]-L-cysteine, 97%, 1g